Literature DB >> 17308358

Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Nobuki Nakamura1, Lori A Erickson, Long Jin, Sabine Kajita, Heyu Zhang, Xiang Qian, Kandelaria Rumilla, Ricardo V Lloyd.   

Abstract

The accurate diagnosis of differentiated thyroid tumors is very important for clinical management of patients. The histopathological distinction between some types of differentiated thyroid tumors can be very difficult even for experienced pathologists. We used immunohistochemical markers from published data obtained from DNA expression profiling, tissue microarray analysis, and immunohistochemistry to analyze a series of 157 thyroid tumors and 5 normal thyroids. These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p < 0.0001). A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma. Because individual tumors may not express some of these markers, the use of a panel of antibodies is recommended. These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17308358     DOI: 10.1385/ep:17:3:213

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  32 in total

1.  Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Authors:  P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

Review 2.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.

Authors:  M Miettinen; P Kärkkäinen
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

4.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Authors:  E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

5.  Discrimination of benign and malignant thyroid nodules by molecular profiling.

Authors:  David J Finley; Baixin Zhu; Catherine B Barden; Thomas J Fahey
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

6.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Authors:  Mary B Casey; Christine M Lohse; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

7.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

8.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

9.  Expression of monoclonal antibody-defined epitopes of keratin 19 in human tumours and cultured cells.

Authors:  J Bártek; J Bártková; J Schneider; J Taylor-Papadimitriou; J Kovarík; A Rejthar
Journal:  Eur J Cancer Clin Oncol       Date:  1986-12

10.  High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.

Authors:  S J Raphael; G McKeown-Eyssen; S L Asa
Journal:  Mod Pathol       Date:  1994-04       Impact factor: 7.842

View more
  14 in total

Review 1.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

Authors:  Husain A Saleh; Bo Jin; John Barnwell; Opada Alzohaili
Journal:  Diagn Pathol       Date:  2010-01-26       Impact factor: 2.644

3.  In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.

Authors:  Zhenying Guo; Heather Hardin; Celina Montemayor-Garcia; Sofia Asioli; Alberto Righi; Francesca Maletta; Anna Sapino; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

4.  A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid.

Authors:  Priscilla Verhulst; Patrick Devos; Sébastien Aubert; David Buob; Isaac Cranshaw; Christine Do Cao; François Pattou; Bruno Carnaille; Jean-Louis Wemeau; Emmanuelle Leteurtre
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

5.  Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.

Authors:  Tijana Isic Dencic; Dubravka Cvejic; Ivan Paunovic; Svetislav Tatic; Marija Havelka; Svetlana Savin
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

6.  Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility.

Authors:  Véronique Hofman; Sandra Lassalle; Christelle Bonnetaud; Catherine Butori; Céline Loubatier; Marius Ilie; Olivier Bordone; Patrick Brest; Nicolas Guevara; José Santini; Brigitte Franc; Paul Hofman
Journal:  Virchows Arch       Date:  2009-06-20       Impact factor: 4.064

7.  HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.

Authors:  Qandeel Sadiq; Radhika Sekhri; Daniel T Dibaba; Qi Zhao; Shweta Agarwal
Journal:  World J Surg Oncol       Date:  2021-05-08       Impact factor: 2.754

8.  Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid.

Authors:  Hans-Juergen Schulten; Zuhoor Al-Mansouri; Ibtisam Baghallab; Nadia Bagatian; Ohoud Subhi; Sajjad Karim; Hosam Al-Aradati; Abdulmonem Al-Mutawa; Adel Johary; Abdulrahman A Meccawy; Khalid Al-Ghamdi; Osman Al-Hamour; Mohammad Hussain Al-Qahtani; Jaudah Al-Maghrabi
Journal:  BMC Genomics       Date:  2015-01-15       Impact factor: 3.969

Review 9.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

10.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Authors:  Duško Dunđerović; Jasmina Marković Lipkovski; Ivan Boričic; Ivan Soldatović; Vesna Božic; Dubravka Cvejić; Svetislav Tatić
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.